Insight Molecular Diagnostics Inc. - Common Stock, no par value (IMDX)

Q: What does CUSIP 68235C206 represent in this 13F holders report?

CUSIP 68235C206 is the security identifier for IMDX - Insight Molecular Diagnostics Inc. - Common Stock, no par value used to aggregate holder disclosures.

Q: How many institutions held IMDX - Insight Molecular Diagnostics Inc. - Common Stock, no par value in Q1 2026?

17 institutional investors reported IMDX - Insight Molecular Diagnostics Inc. - Common Stock, no par value for Q1 2026. Use the holders table for investor-level position and value details.

CUSIP: 68235C206

Q1 2026 13F Holders as of 31 Mar 2026

Type / Class: Equity / Common Stock, no par value
Shares outstanding: 32,330,312
Total 13F shares: 1,917,851
Share change: +185,454
Total reported value: $6,290,010
Price per share: $3.28
Number of holders: 17
Value change: +$428,618
Number of buys: 7
Number of sells: 1

Quarterly Holders Quick Answers

What is CUSIP 68235C206?
CUSIP 68235C206 identifies IMDX - Insight Molecular Diagnostics Inc. - Common Stock, no par value in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Previous quarter: Q4 2025

Recent filing periods for CUSIP 68235C206:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of IMDX - Insight Molecular Diagnostics Inc. - Common Stock, no par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
BROADWOOD CAPITAL INC	13F	Company	35%	11,410,100	$85,575,750	—	31 Dec 2025	13F
AWM Investment Company, Inc.	13F 13D/G	Company	10% from 13D/G	2,814,230	$21,106,725	—	31 Dec 2025	13F 13D/G
PURA VIDA INVESTMENTS, LLC	13F 3/4/5	Company · 10%+ Owner	2.9%	947,134	$7,103,505	—	31 Dec 2025	13F 3/4/5
Patrick W. Smith	3/4/5 13D/G	10%+ Owner	10% from 13D/G	3,258,485	$6,679,894	—	07 Feb 2025	3/4/5 13D/G
VANGUARD GROUP INC	13F	Company	1.6%	526,675	$3,950,064	—	31 Dec 2025	13F
Andrea S. James	3/4/5	Chief Financial Officer	— mixed-class rows	525,965 mixed-class rows	$1,777,524	—	26 Mar 2026	3/4/5
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.71%	230,971	$1,733,670	—	31 Dec 2025	13F
BlackRock, Inc.	13F	Company	0.41%	131,361	$985,208	—	31 Dec 2025	13F
Josh Riggs	3/4/5	CEO and President, Director	— mixed-class rows	579,874 mixed-class rows	$674,529	—	26 Mar 2026	3/4/5
BIO-RAD LABORATORIES, INC.	13D/G	—	9.7%	2,764,078	$608,097	$0	10 Feb 2025	13D/G
683 Capital Management, LLC	13F	Company	0.24%	77,204	$579,030	—	31 Dec 2025	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.22%	72,451	$543,383	—	31 Dec 2025	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	0.19%	61,377	$460,328	—	31 Dec 2025	13F
Andrew Arno	3/4/5	Director	— mixed-class rows	174,358 mixed-class rows	$381,104	—	01 Jul 2025	3/4/5
NORTHERN TRUST CORP	13F	Company	0.15%	48,858	$366,435	—	31 Dec 2025	13F
STATE STREET CORP	13F	Company	0.15%	47,754	$358,155	—	31 Dec 2025	13F
JANE STREET GROUP, LLC	13F	Company	0.13%	42,469	$318,517	—	31 Dec 2025	13F
FNY Investment Advisers, LLC	13F	Company	0.13%	40,584	$304,000	—	31 Dec 2025	13F
MORGAN STANLEY	13F	Company	0.11%	35,913	$269,348	—	31 Dec 2025	13F
Qube Research & Technologies Ltd	13F	Company	0.09%	28,351	$212,633	—	31 Dec 2025	13F
OMERS ADMINISTRATION Corp	13F	Company	0.08%	26,164	$196,230	—	31 Dec 2025	13F
OSAIC HOLDINGS, INC.	13F	Company	0.07%	24,136	$181,019	—	31 Dec 2025	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.07%	23,965	$179,738	—	31 Dec 2025	13F
John Peter Gutfreund	3/4/5	Former Director	— mixed-class rows	760,000 mixed-class rows	$153,654	—	30 Jun 2023	3/4/5
Ronald Asbury Andrews	3/4/5	Former CEO, Director	— mixed-class rows	633,212 mixed-class rows	$125,332	—	01 Dec 2022	3/4/5
CITADEL ADVISORS LLC	13F	Company	0.05%	15,647	$117,353	—	31 Dec 2025	13F
Alfred D. Kingsley	3/4/5	Director	— mixed-class rows	597,878 mixed-class rows	$109,143	—	23 Jun 2023	3/4/5
Andrew J. Last	3/4/5	Director	— mixed-class rows	69,509 mixed-class rows	$104,303	—	01 Jul 2025	3/4/5
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.04%	13,400	$100,500	—	31 Dec 2025	13F
Hudson Bay Capital Management LP	13F	Company	0.04%	13,061	$97,958	—	31 Dec 2025	13F
Lou Silverman	3/4/5	Director	— mixed-class rows	66,564 mixed-class rows	$96,528	—	01 Jul 2025	3/4/5
Gisela Paulsen	3/4/5	Former President and COO	— class O/S missing	366,500	$78,761	—	16 Dec 2022	3/4/5
Private Advisor Group, LLC	13F	Company	0.03%	10,416	$78,120	—	31 Dec 2025	13F
Li Yu	3/4/5	VP Cntrllr/Prncpl Acctng Offcr	— mixed-class rows	41,872 mixed-class rows	$76,536	—	18 May 2022	3/4/5
James Yang Liu	3/4/5	VP ACCT, Cntlr, Treasurer, PAO	— mixed-class rows	34,289 mixed-class rows	$66,509	—	26 Mar 2026	3/4/5
Ross Douglas T.	3/4/5	Former CSO	— class O/S missing	234,114	$50,311	—	21 Dec 2022	3/4/5
EverSource Wealth Advisors, LLC	13F	Company	0.02%	5,000	$37,500	—	31 Dec 2025	13F
Cavan M. Redmond	3/4/5	Director	— class O/S missing	120,863	$25,973	—	24 Jun 2022	3/4/5
UBS Group AG	13F	Company	0.01%	2,941	$22,058	—	31 Dec 2025	13F
Mitchell S. Levine	3/4/5	Chief Financial Officer	— mixed-class rows	174,580 mixed-class rows	$18,713	—	15 Mar 2022	3/4/5
Jennifer Levin Carter	3/4/5	Director	— mixed-class rows	75,500 mixed-class rows	$6,554	—	15 Aug 2022	3/4/5
Melinda Griffith	3/4/5	Director	— mixed-class rows	75,000 mixed-class rows	$6,447	—	15 Aug 2022	3/4/5
ORG Partners LLC	13F	Company	0%	450	$3,375	—	31 Dec 2025	13F
BANK OF AMERICA CORP /DE/	13F	Company	0%	335	$2,513	—	31 Dec 2025	13F
Tower Research Capital LLC (TRC)	13F	Company	0%	250	$1,875	—	31 Dec 2025	13F
SBI Securities Co., Ltd.	13F	Company	0%	185	$1,388	—	31 Dec 2025	13F
JPMORGAN CHASE & CO	13F	Company	0%	154	$1,155	—	31 Dec 2025	13F
BNP PARIBAS FINANCIAL MARKETS	13F	Company	0%	30	$225	—	31 Dec 2025	13F
Piscataqua Savings Bank	13F	Company	0%	25	$187	—	31 Dec 2025	13F
ALBION FINANCIAL GROUP /UT	13F	Company	0%	7	$53	—	31 Dec 2025	13F

Institutional Holders of Insight Molecular Diagnostics Inc. - Common Stock, no par value (IMDX) as of Q1 2026

As of 31 Mar 2026, Insight Molecular Diagnostics Inc. - Common Stock, no par value (IMDX) was held by 17 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 1,917,851 shares. The largest 10 holders included PURA VIDA INVESTMENTS, LLC, VANGUARD CAPITAL MANAGEMENT LLC, FNY Investment Advisers, LLC, VANGUARD FIDUCIARY TRUST CO, UBS Group AG, Flatrock Wealth Partners LLC, Private Advisor Group, LLC, Vanguard Global Advisers, LLC, CITIGROUP INC, and Ascentis Independent Advisors. This page lists 17 institutional shareholders reporting positions in this security for the Q1 2026 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q1 2026 vs Q4 2025 Across Filers

Q4 2025 holders

Q1 2026 holders

Holder diff

-17

Investor	Q4 2025 Shares	Q1 2026 Shares	Share Diff	Share Chg %	Q4 2025 Value $	Q1 2026 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.